Funding
← Back to your selection

Duquesne Family Office

Activity from announced rounds

Activity in this selectionOct 17, 2026 · Jul 20, 2026

Duquesne Family Office is the family-office investor identified by Precision Neuroscience and Cellares.

Recorded funding activity

Its recorded company activity also includes Epicrispr’s epigenetic medicines, Ratio’s radiopharmaceuticals and SonoThera’s ultrasound-mediated genetic-medicine delivery. These are separate therapeutic approaches. The institutional record remains distinct from Stanley Druckenmiller’s personal investment identity.

Sources
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$160M
2 disclosed · full round size, not this investor’s share

By stage

Series C+2

By primary sector

Biotech2

By country

United States2

Rounds

2 in this selection
Ratio Therapeutics

Developing best-in-class radiopharmaceuticals for cancer treatment

$70MSeries C
Role not disclosed